Artemisinin partial resistance is spreading across East Africa via Kelch13 mutations

Validated Kelch13 mutations conferring artemisinin partial resistance have emerged independently in multiple East African countries, with alarming prevalence: R561H at 52% in Uganda, R622I at 68% in Eritrea, C469F at 59% in Uganda, and P441L at 69% in Uganda and 20% in Tanzania. This is the single most dangerous development in global malaria control because artemisinin-based combination therapies (ACTs) are the only first-line treatment for P. falciparum malaria, and there is no replacement drug class ready at scale. When artemisinin resistance takes hold, treatment failure rates climb, patients stay parasitemic longer, and transmission increases. The catastrophic precedent is Southeast Asia, where full artemisinin resistance led to treatment failure rates above 50% and the elimination of multiple ACT regimens. If the same trajectory plays out in Africa, where 95% of the world's 249 million malaria cases occur, the death toll could revert to pre-ACT levels of over 1 million per year. The problem persists because resistance emerges under drug pressure from widespread ACT use, monotherapy availability in unregulated pharmacies, incomplete treatment courses, and substandard drug quality. Cross-border population movement spreads resistant strains between countries faster than surveillance systems can track them.